Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer

Ovarian cancer has the highest facility rate among gynaecological tumours. Current therapies including PARP inhibitors have a defect that ovarian tumour is easy to recurrent and become resistant to therapy. To solve this problem, we found that BRD4 inhibitor AZD5153 and PARP inhibitor olaparib had a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yuhan, Liu, Chen, You, Lixin, Li, Xi, Chen, Gang, Fan, Junpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983312/
https://www.ncbi.nlm.nih.gov/pubmed/36753396
http://dx.doi.org/10.1111/jcmm.17683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983312/
https://www.ncbi.nlm.nih.gov/pubmed/36753396
http://dx.doi.org/10.1111/jcmm.17683

Ejemplares similares